The news release titled "Jubilant Therapeutics Announces Oral Presentation of Phase 1 Clinical Results for JBI-802, a First-in-Class Oral Dual LSD1/HDAC6 Inhibitor, in Essential Thrombocythemia and Related Myeloproliferative Neoplasms at the 68th ASH Annual Meeting" issued 10-Nov-2026 is being retracted and should be disregarded. An updated, final version of this release will shortly follow.

SOURCE Jubilant Therapeutics